ASNS

Asparagine synthetase [glutamine-hydrolyzing] · P08243 · ASNS on Sugi Atlas →

102 patent compounds predicted against ASNS, 97 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Adenosine Phosphate (SCHEMBL9455662)	0.69	1/20
Adenosine Phosphate (SCHEMBL2125401)	0.69	1/20
Adenosine Phosphate (SCHEMBL2406483)	0.69	1/20
Adenosine Phosphate (SCHEMBL5890078)	0.69	1/20
Adenosine Phosphate (SCHEMBL15670772)	0.69	1/20
Adenosine Phosphate (SCHEMBL15670779)	0.68	1/20
Adenosine Phosphate (SCHEMBL15671039)	0.68	1/20
SCHEMBL2508954	0.67	1/20
Adenosine Phosphate (SCHEMBL15670584)	0.67	1/20
Adenosine Phosphate (SCHEMBL15670792)	0.66	1/20
Adenosine Phosphate (SCHEMBL7225652)	0.66	1/20
Adenosine Phosphate (SCHEMBL15670547)	0.66	1/20
Adenosine Phosphate (SCHEMBL15670721)	0.66	1/20
Adenosine Phosphate (SCHEMBL1331852)	0.65	1/20
Adenosine Phosphate (SCHEMBL3514918)	0.65	1/20
Adenosine Phosphate (SCHEMBL8365323)	0.65	1/20
Adenosine Phosphate (SCHEMBL15671063)	0.65	1/20
Adenosine Phosphate (SCHEMBL17144429)	0.65	1/20
SCHEMBL31729520	0.64	1/20
Adenosine Phosphate (SCHEMBL7225350)	0.64	1/20

Clinical trials — most relevant to ASNS by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Nutrition for Colorectal Cancer Patients and Neutrophil Functions	PHASE4	COMPLETED
Supplemental Enteral Protein in Critical Illness	PHASE3	COMPLETED
Efficacy of L-Ornithine-L-Aspartate in Cirrhotics With Hepatic Encephalopathy	PHASE3	COMPLETED
Treatment of Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis-Child C	PHASE3	ACTIVE_NOT_RECRUITING
N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia	PHASE2/PHASE3	UNKNOWN
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
GRASPA Treatment for Patients With Acute Myeloblastic Leukemia	PHASE2	COMPLETED
Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate	PHASE2	WITHDRAWN
A Phase I/II Open-label Safety and Efficacy Study of LNP.UCD.ABE in Patients With Urea Cycle Disorders.	PHASE1/PHASE2	NOT_YET_RECRUITING
Lithium and Acetate for Canavan Disease	PHASE2	WITHDRAWN
Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders	PHASE2	COMPLETED
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia	PHASE2	WITHDRAWN
Effect of Arginine- and Glutamine-based Oral Formulations on Salivary Biomarkers and Clinical Severity of Radiation-induced Oral Mucositis in Head and Neck Cancer: A Randomized Controlled Trial	PHASE2	COMPLETED
Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene.	PHASE1/PHASE2	COMPLETED
Anaplerotic Therapy in Propionic Acidemia	PHASE1	COMPLETED
GTA-Glyceryltriacetate for Canavan Disease	PHASE1	UNKNOWN
Glutamine Supplementation in People With Immune Dysregulation	EARLY_PHASE1	WITHDRAWN
Glutamine and Traumatic Brain Injury	EARLY_PHASE1	UNKNOWN
Correlation of Polymorphisms of Lipoprotein Lipase (LpL) and Apolipoprotein E (Apo E) With Lipid Profile of Children With Acute Lymphoblastic Eukaemia During Therapy With L - Asparaginase.	nan	UNKNOWN
Oral Glutamine in Cardiopulmonary Bypass	nan	COMPLETED
The Glucagonotropic Effect of Amino Acids in Humans	nan	COMPLETED
Multi-omics Study in Citrin Deficiency	nan	ACTIVE_NOT_RECRUITING
Pharmacokinetics of Asparaginase and Antibody Formation in Interfant-06	nan	COMPLETED
Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione	nan	COMPLETED
Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms	nan	COMPLETED
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions	nan	COMPLETED
Quality of Protein From the Common Bean	nan	COMPLETED
Evaluation of Blood and Cardiac Protein O-GlcNAcylation Levels in Cardiac Surgery in Children	nan	RECRUITING
Effect of Glutamine Supplemented Nutrition Support on Protein and Glutamine Metabolism in Burns	nan	WITHDRAWN
Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal Carcinoma	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a ASNS binder may also engage these)

Protein	Name	Similarity
Q5R6W9	—	1.000	Q5R6W9 →
P19891	—	1.000	P19891 →
Q5ZJU3	—	1.000	Q5ZJU3 →
P17714	—	1.000	P17714 →
Q61024	—	1.000	Q61024 →
Q1LZA3	—	0.998	Q1LZA3 →
P49088	—	0.998	P49088 →
Q9LFU1	—	0.976	Q9LFU1 →
P49078	—	0.974	P49078 →
P49092	—	0.972	P49092 →
P49093	—	0.971	P49093 →
P19252	—	0.970	P19252 →
O24338	—	0.970	O24338 →
P78753	—	0.969	P78753 →
Q27601	—	0.969	Q27601 →
P49091	—	0.969	P49091 →
Q93YQ3	—	0.969	Q93YQ3 →
Q9LV77	—	0.967	Q9LV77 →
Q14194	—	0.967	Q14194 →
P40510	—	0.966	P40510 →
Q43011	—	0.966	Q43011 →
P31752	—	0.965	P31752 →
Q62188	—	0.965	Q62188 →
Q9S7X6	—	0.965	Q9S7X6 →
Q6GP70	—	0.964	Q6GP70 →
I1S3K8	—	0.964	I1S3K8 →
Q63ZU0	—	0.964	Q63ZU0 →
O24661	—	0.964	O24661 →
Q6ZFT5	—	0.964	Q6ZFT5 →
Q60HD9	—	0.964	Q60HD9 →